EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is expected to report first quarter earnings results, before market open, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate first quarter loss of $ 0.03 per share.
Looking ahead, the full year loss are expected at $ 0.33 per share on the revenues of $ 32.14 million.
Previous Quarter Performance
EyePoint Pharmaceuticals, Inc. revealed loss for the fourth quarter of $ 0.10 per share, from the revenue of $ 4.12 million. The quarterly revenues reduced 38.42 percent compared with the same quarter last year. According to street consensus, EYPT was expected to report 4Q20 loss of $ 0.10 per share from revenue of $ 3.73 million. The top line results outshined analysts by $ 0.39 million or 10.46 percent.
Stock Performance
Shares of EyePoint Pharmaceuticals, Inc. traded up $ 0.02 or 6.05 percent on Wednesday, reaching $ 0.40 with volume of 952.20 thousand shares. EyePoint Pharmaceuticals, Inc. has traded high as $ 0.41 and has cracked $ 0.37 on the downward trend
The closing price of $ 0.40, representing a 8.57 % increase from the 52 week low of $ 0.35 and a 83.97 % decrease over the 52 week high of $ 2.37.
The company has a market capital of $ 53.68 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 9th October 2020, upgraded by HC Wainwright to Buy from Neutral rating.
Conference Call
EyePoint Pharmaceuticals, Inc. will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 1Q21 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website eyepointpharma.com
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. The company also offers DEXYCU (dexamethasone intraocular suspension), an intraocular product for the treatment of postoperative ocular inflammation; and Vitrasert (ganciclovir), a sustained release implant for the treatment of cytomegalovirus retinitis.
